IQGAP1 promotes pancreatic cancer progression and epithelial-mesenchymal transition (EMT) through Wnt/β-catenin signaling

Wei Hu1,2, Zhongxia Wang2, Shan Zhang2, Xian Lu2, Junyi Wu2, Kuanyong Yu2, Anlai Ji2, Wei Lu4, Zhong Wang1, Junhua Wu3 & Chunping Jiang2

IQ motif-containing GTPase-activating protein 1 (IQGAP1) is a scaffold protein that participates in several cellular functions, including cytoskeletal regulation, cell adhesion, gene transcription and cell polarization. IQGAP1 has been implicated in the tumorigenesis and progression of several human cancers. However, the role of IQGAP1 in pancreatic ductal adenocarcinoma (PDAC) is still unknown. We found that IQGAP1 expression was an independent prognostic factor for PDAC. IQGAP1 upregulation significantly promoted cell proliferation, migration, invasion and epithelial-mesenchymal transition (EMT), whereas IQGAP1 downregulation impaired its oncogenic functions. Overexpression of IQGAP1 increased the protein level of Dishevelled2 (DVL2) and enhanced canonical Wnt signaling as evidenced by increased DVL2 level, β-catenin transcriptional activity, β-catenin nuclear translocation and expression of the direct target genes of β-catenin (cyclin D1 and c-myc). In contrast, knockdown of IQGAP1 decreased the level of DVL2 and attenuated Wnt/β-catenin signaling. In vivo results revealed that IQGAP1 promoted tumor growth and metastasis. Co-immunoprecipitation studies demonstrated that IQGAP1 interacted with both DVL2 and β-catenin. Moreover, knockdown of DVL2 reversed IQGAP1-induced EMT. Our findings thus confirmed that IQGAP1 could be used as a potential target for PDAC treatment.

Pancreatic cancer (PC) remains one of the most lethal malignancies with a 5-year survival rate of less than 5%1. Despite progress in treatment strategies, the decrease in mortality rate for this disease is still slow2 due to aggressive growth, distant metastasis, chemoresistance and difficulties in early diagnosis3–5. Pancreatic ductal adenocarcinoma (PDAC) accounts for more than 95% of all PC cases6. Therefore, there is an urgent need to explore diagnostic molecular biomarkers and targets with high therapeutic efficacy to improve the prognosis of PDAC patients.

As one of the evolutionally conserved scaffold protein family members, IQ motif-containing GTPase-activating protein 1 (IQGAP1) includes five domains, namely, the calponin homology domain interacting with F-actin, GAP-related domain interacting with small GTPases (Rac1 and Cdc42), poly-proline protein-protein domain interacting with ERK, IQ domain interacting with four IQ motifs and RasGAP C-terminus7. Several cellular functions are regulated by the multidomain structures of IQGAP1 through its binding with many other partners, which is mainly mediated by the RGCT or IQ regions8,9. For example, IQGAP1 functions as a scaffold in the MEK/ERK cascade by binding to MEK1/2, ERK1/2 and B-Raf via its IQ region10. Accumulating evidence indicates that IQGAP1 is an oncogene11,12. IQGAP1 expression has been reported to be upregulated in several types of human cancer tissues and cell lines, such as hepatocellular carcinoma12, thyroid cancer13, breast cancer14, esophageal squamous cell carcinoma15, non-small cell lung cancer16 and PC17.
However, the function and underlying mechanism of IQGAP1 in PDAC have not been fully evaluated. The present study aimed to investigate the prognostic values and biological functions of IQGAP1 and the associated molecular mechanisms in PDAC. We first evaluated the expression level of IQGAP1 in PDAC tissues using immunohistochemistry (IHC) and investigated the association of IQGAP1 expression level with clinicopathological features and patient survival. Then, we studied the role of IQGAP1 in the progression of PDAC by using both in vivo and in vitro models. Finally, we explored the effect of IQGAP1 on the Wnt/β-catenin signaling pathway in PDAC cells.

Results
Expression of IQGAP1 in PDAC tissues is significantly higher than that in adjacent normal tissues. The expression of IQGAP1 in 87 PDAC tissues identified by IHC was classified into two groups: the low-IQGAP1 group (IQGAP1L) (that is, staining index (SI) ≤ 4) containing 30 samples and the high-IQGAP1 group (IQGAP1H) (that is, SI > 4) containing 57 samples. The percentage of high expression of IQGAP1 (65.5%, 57/87) in PDAC tissues was significantly higher than that (15.9%, 11/69) in matched peritumor tissues (P < 0.001, Fig. 1A,B). Compared with that in paired adjacent tissues, the protein and mRNA expression of IQGAP1 in PDAC tissue samples from 4 different patients was upregulated (Fig. 1C,D). The analysis of the relationship between the expression levels of IQGAP1 and clinicopathologic variables showed that IQGAP1 protein expression is significantly correlated with histological differentiation (P = 0.034) and pathological N stage (P = 0.030) (Table 1).

IQGAP1 expression is an independent prognostic predictor for PDAC patients. We further investigated whether IQGAP1 can be used as a prognostic indicator in PDAC patients. Only 23 patients were still alive by the last follow-up. Kaplan-Meier analysis and log-rank test were used to explore the relationship between IQGAP1 expression levels and clinical follow-up information in 87 PDAC patients. PDAC patients in the IQGAP1H group had significantly poorer overall survival (OS) rates than patients in the IQGAP1L group (P = 0.002, Fig. 1E). Univariate and multivariate Cox analyses were used to assess the correlations between the
immunohistochemical data for IQGAP1 expression and clinicopathologic features (Supplementary Table S1). The median OS of patients in the IQGAP1H group and IQGAP1L group was 10.0 months (95% confidence interval [CI] 8.325–11.675) and 33.0 months (95% CI 0.085–65.915), respectively. Univariate analysis indicated that the following variables were significantly related to OS: histological differentiation (P = 0.047), N stage (P < 0.001), and IQGAP1 expression (P = 0.004). In multivariate analysis using Cox proportional hazards models, N1 stage (HR 2.786; 95% CI 1.617–4.800; P < 0.001), poor tumor differentiation (HR 1.969; 95% CI 1.107–3.500; P = 0.021), and high IQGAP1 expression (hazard ratio [HR] 1.880; 95% CI 1.049–3.367; P = 0.034) were correlated with OS (Supplementary Table S1). Therefore, IQGAP1 expression is an independent prognostic predictor in PDAC patients.

Successful inhibition of IQGAP1 following siRNA transfection in CFPAC-1 and SW1990 cells. The expression of IQGAP1 was detected in BxPc-3, SW1990, Capan-2, CFPAC-1, PANC-1, and hTERT-HPNE cells by qRT-PCR and western blotting. Higher expression of IQGAP1 mRNA and protein was observed in PC cells than in hTERT-HPNE cells and the expression level of IQGAP1 protein in SW1990 and CFPAC-1 cells is the highest among all PC cells (Fig. 2A,B). To further assess the role of IQGAP1 in PDAC, we knocked down IQGAP1 in PC cells. SW1990 and CFPAC-1 cells were selected for IQGAP1 knockdown by siRNA. The interference efficiency of two siRNAs for IQGAP1 was confirmed through comparison with negative controls at both mRNA and protein levels. siRNA#2 (siIQGAP1) could significantly decrease IQGAP1 mRNA and protein levels and was used for further function and mechanism investigation (Fig. 2C,D). As indicated by immunofluorescence, compared with that in control cells, IQGAP1 expression was downregulated in siRNA#2-transfected cells (Fig. 2E). Secondary antibody only staining was used as negative control (Supplementary Fig. 1A).

Knockdown of IQGAP1 represses the proliferation, migration and invasion of PC cells. Given that high IQGAP1 expression was significantly related to lymph node metastasis in PC tissues (Table 1), we hypothesized that IQGAP1 may promote the proliferation, migration and invasion of PC cells. Indeed, knockdown of IQGAP1 markedly inhibited cell growth and cell proliferation (Fig. 3A,B). Both wound healing assay and transwell

| Variables | Number | IQGAP1 (%) | IQGAP1H (%) | P* |
|-----------|--------|------------|-------------|----|
| Sex       |        |            |             |    |
| Male      | 54     | 20 (37.0)  | 34 (63.0)   | 0.521 |
| Female    | 33     | 10 (30.3)  | 23 (69.7)   |    |
| Age       |        |            |             |    |
| ≤61       | 44     | 16 (36.4)  | 28 (63.6)   | 0.709 |
| >61       | 43     | 14 (32.6)  | 29 (67.4)   |    |
| Tumor location | | | |    |
| Pancreatic head | 56   | 16 (28.6)  | 40 (71.4)   | 0.119 |
| Non-head  | 31     | 14 (45.2)  | 17 (54.8)   |    |
| Tumor size (cm) | | | |    |
| <4        | 26     | 5 (19.2)   | 21 (80.8)   | 0.051 |
| ≥4        | 61     | 25 (41.0)  | 36 (59.0)   |    |
| Histological differentiation | | | |    |
| Well-moderate | 66   | 27 (40.9)  | 39 (59.1)   | 0.034* |
| Poor      | 21     | 3 (14.3)   | 18 (85.7)   |    |
| TNM stage |        |            |             |    |
| I+II      | 86     | 30 (34.9)  | 56 (65.1)   | 1b |
| III+IV    | 1      | 0 (0)      | 1 (100)     |    |
| T classification | | | | 0.397 |
| T1/T2     | 68     | 25 (36.8)  | 43 (63.2)   |    |
| T3        | 19     | 5 (26.3)   | 14 (73.7)   |    |
| N classification | | | |    |
| N0        | 47     | 21 (44.7)  | 26 (55.3)   | 0.030 |
| N1        | 40     | 9 (22.5)   | 31 (77.5)   |    |
| M classification | | | |    |
| M0        | 86     | 30 (34.9)  | 56 (65.1)   | 1b |
| M1        | 1      | 0 (0)      | 1 (100)     |    |
| Perineural invasion | | | |    |
| Present   | 35     | 10 (28.6)  | 25 (71.4)   | 0.341 |
| Absent    | 52     | 20 (38.5)  | 32 (61.5)   |    |

Table 1. Correlation between IQGAP1 expression and clinicopathological variables in patients with PDAC.

*Median age; bFisher’s exact test. *P < 0.05 indicates a significant association among the variables.
To prevent potential confounding factors brought by cell proliferation, we examined in detail the difference of proliferation between cells with different transfection conditions. Firstly, raw optical density data from CCK-8 assay indicated that at 24 h (the time point when cells were subjected to wound healing assay), no significant difference of cell proliferation was observed between cells with different IQGAP1 expression conditions (Figs 3A, 4B). Secondly, during wound healing assay, cells were cultured under serum-free condition, which further eliminated potential effect of cell proliferation on migration. Lastly, proliferation assay mimicking culture condition during wound healing assay showed little difference of cell proliferation (Supplementary Fig. 1B). Our results showed that cell migration was markedly inhibited in IQGAP1 knockdown cells as compared with control cells (Fig. 3C,D). The effect of IQGAP1 silencing on migratory ability in CFPAC-1 cells seemed more pronounced than in SW1990 in wound healing assays, while the opposite occurred in transwell migration assays, which maybe resulted from that the size of SW1990 cells is smaller than that of CFPAC-1 cells, so in transwell assays SW1990 cells may pass through the 8-µm chamber easier than CFPAC-1 cells. Western blotting and qRT-PCR were used to confirm the stable interference of IQGAP1 expression (Fig. 3E).

In vivo xenograft assays confirmed that on day 24, the volume and weight of tumors generated from SW1990 cells with silenced IQGAP1 expression (SW1990-shIQGAP1) were smaller than those of tumors generated from negative control cells (SW1990-shNC) (mean volumes of 205 mm³ versus 942 mm³, respectively). IHC staining showed that pancreatic tumors formed by SW1990-shIQGAP1 cells had lower IQGAP1 expression than those formed by SW1990-shNC cells (Fig. 3G). Additionally, liver metastasis models were constructed by orthotopically injecting shIQGAP1 and shNC cells into the major pancreatic duct of nude mice. Three months after the injection, the mice were euthanized, and liver metastases were counted and fixed in 10% formalin. The average number of visible liver metastatic nodules in the shIQGAP1 group was markedly lower than that in the shNC group (Fig. 3H,I). Therefore, the inhibition of IQGAP1 expression suppresses the proliferation of PC cells in vitro and in vivo, migration and invasiveness of PC cells in vitro, and the metastasis of PC cells in vivo.

Overexpression of IQGAP1 promotes the proliferation and migration of human PC cells. To further assess the oncogenic role of IQGAP1, we next overexpressed IQGAP1 in the PC cell line PANC-1 (PANC-1-IQGAP1 cells) by transiently transfecting PANC-1 cells with IQGAP1 plasmids. Western blotting and qRT-PCR analysis confirmed a significant increase in IQGAP1 expression in PANC-1-IQGAP1 cells relative to that in control cells (Fig. 4A). Overexpression of IQGAP1 in PANC-1 cells induced faster cell growth and stronger migratory capability than those in control cells (Fig. 4B,C). Furthermore, CCK-8 and colony formation assays showed that the PANC-1-IQGAP1 cells demonstrated a considerable growth advantage relative to the respective control cells (Fig. 4B,C). Meanwhile, more
accelerated wound healing ability and distinctly higher migration rates were observed in PANC-1-IQGAP1 cells than in the control cells by wound healing assay and transwell assay, respectively (Fig. 4D,E). Thus, IQGAP1 overexpression positively regulates the proliferation and migration of PC cells in vitro.

Figure 3. Knockdown of IQGAP1 inhibits the proliferation, migration and invasion of PC cells. Knockdown of IQGAP1 inhibits cell growth, as determined by CCK-8 (A) and colony formation assays (B). (C) Representative images of wound healing by IQGAP1 knockdown (siRNA), control (siNC) and wild-type (WT) cells were photographed at 0, 24 and 48 hours after scraping. (D) Cell migration was measured by transwell assays. Number of migrated cells was exhibited as the mean ± SD of three randomly chosen visual fields from three independent experiments. (E) Western blotting and qRT-PCR were used to confirm the stable interference of IQGAP1 expression. (F) Gross observation of xenograft tumor size. Volume and weight of tumors derived from nude mouse models following IQGAP1 downregulation by shRNA were decreased in vivo. (G) Xenograft tumor tissues were stained with anti-IQGAP1 antibody by IHC. (H) Liver metastatic nodules (black arrow) were evaluated approximately 3 months postinjection (n = 8 per group). (I) Representative results of H&E staining of metastatic nodules in the liver. *P < 0.05, **P < 0.01, and ***P < 0.001. Uncropped western blots are shown in Supplementary Fig. 2.
IQGAP1 interacts with Dishevelled 2 (DVL2) and β-catenin and translocates DVL2 into the nucleus. During early embryogenesis of Xenopus embryos, the binding of IQGAP1 and DVL2 is required for the canonical Wnt/β-catenin pathway, but the correlation between IQGAP1 and DVL2 in PC cell lines have not been studied. We thus examined whether endogenous IQGAP1 interacts with DVL2 and components of the Wnt/β-catenin pathway. Co-IP experiments verified that IQGAP1 and DVL2 interacted with each other in HEK-293T, SW1990 and CFPAC-1 cells (Fig. 5A). In Xenopus embryos, depletion of IQGAP1 can decrease Wnt-induced nuclear accumulation of β-catenin. Therefore, we questioned whether IQGAP1 can also form a complex with β-catenin in PC cells. Co-IP results demonstrated that endogenous IQGAP1 and β-catenin could interact with each other, suggesting that IQGAP1 could associate with DVL2 and β-catenin to form a complex (Fig. 5B). Therefore, IQGAP1 is involved in the formation of the DVL2 and β-catenin complex in PC cells. Subsequently, we examined the effect of IQGAP1 on DVL2 and Wnt signaling. The protein level of DVL2 decreased when IQGAP1 was knocked down and increased when IQGAP1 was overexpressed (Fig. 5C). However, DVL2 mRNA level was not changed in either IQGAP1-overexpressing cells or knockdown cells (Fig. 5D). Immunofluorescence assays showed that knockdown of IQGAP1 inhibited the overall expression of endogenous DVL2 (Fig. 5E), while overexpression of IQGAP1 promoted the nuclear localization of endogenous DVL2 (Fig. 5F).

IQGAP1 mediates Wnt/β-catenin signaling through the regulation of expression and interaction of DVL2 and β-catenin. Given that IQGAP1 binds to both DVL2 and β-catenin, we assessed the effect of IQGAP1 on Wnt/β-catenin activation. Strikingly, inhibition of IQGAP1 downregulated the direct target genes of β-catenin, cyclin D1 and c-myc at both mRNA and protein levels (Fig. 6A,B, Supplementary Fig. 1C). Subcellular fractionation revealed that the downregulation of IQGAP1 expression decreased β-catenin, cyclin D1 and c-myc protein levels in both the cytoplasmic and nuclear fractions (Fig. 6C, Supplementary Fig. 1D,E). Conversely, overexpression of IQGAP1 resulted in increased β-catenin, cyclin D1 and c-myc mRNA and protein levels (Fig. 6A,B, Supplementary Fig. 1C) and enhancement of nuclear accumulation of β-catenin, cyclin D1 and c-myc in PANC-1 cells (Fig. 6D, Supplementary Fig. 1F). Immunofluorescence assays also demonstrated that IQGAP1 regulated both protein level and nuclear translocation of β-catenin, in a similar manner showed in western blotting assays after RNA interference and overexpression of IQGAP1 (Fig. 6E,F).

As IQGAP1 regulated the expression levels and formed complex with DVL2 and β-catenin, it is intriguing to ask whether IQGAP1 plays a role in the interaction between DVL2 and β-catenin. Interestingly, knockdown of IQGAP1 indeed reduced the interaction between DVL2 and β-catenin as demonstrated by Co-IP assay (Fig. 6G). Though expression of IQGAP1 correlates with protein expression levels of β-catenin and DVL2 (Figs 5C, 6A), the ratio between β-catenin and DVL2 in knockdown and overexpression cells showed no difference compared with negative control groups respectively, indicating the expression of IQGAP1 may have altered the levels of β-catenin and DVL2 to a similar degree (Supplementary Fig. 1G). Interestingly, the ratio between co-immunoprecipitated
β-catenin and DVL2 decreased in IQGAP1 knockdown cells, indicating IQGAP1 not only regulated protein levels of β-catenin and DVL2 but also mediated their interactions (Supplementary Fig. 1H). Taken together, IQGAP1 may regulate the expression and interaction of β-catenin and DVL2, which subsequently regulates the Wnt/β-catenin signaling pathway.

IQGAP1 promotes epithelial-mesenchymal transition (EMT) and proliferation through the canonical Wnt signaling pathway by interacting with DVL2. It is well known that E-cadherin, N-cadherin, and Vimentin are specific markers for the EMT process. We thus tested whether IQGAP1-mediated changes in DVL2 were responsible for changes in EMT. As shown in Fig. 7A, SW1990 and CFPAC-1 cells with IQGAP1 knockdown expressed a higher level of the epithelial marker E-cadherin and lower levels of the mesenchymal markers N-cadherin and Vimentin than did the respective negative control cells. The levels of EMT-activating transcription factors Snail, Slug, Twist1 and ZEB1 were also decreased in SW1990 and CFPAC-1 cells with IQGAP1 knockdown. Conversely, overexpression of IQGAP1 in PANC-1 cells led to the opposite effects (Fig. 7A, Supplementary Fig. 1I–K). Overall, these findings demonstrate that IQGAP1 regulates EMT in PC cells.
Because IQGAP1 increases DVL2 protein levels, we questioned whether the expression of EMT markers induced by IQGAP1 is attributable for the enhancement in DVL2 stability. To this end, we co-transfected IQGAP1 expression plasmid and siDVL2 in PANC-1 cells and examined the levels of E-cadherin and N-cadherin. Indeed, siDVL2 reversed the decrease in the expression of E-cadherin and increase in the expression of N-cadherin induced by IQGAP1 overexpression (Fig. 7B), suggesting that EMT regulated by IQGAP1 is mediated by DVL2. Next, we examined the effect of co-transfection of IQGAP1 and siDVL2 on cell migration. In line with the above results, the enhancement in cell migration by the overexpression of IQGAP1 in PANC-1 cells was prevented by siDVL2 transfection as demonstrated using wound healing and transwell migration assays (Fig. 7C,D). Therefore, the downregulation of DVL2 can reverse the EMT process enhanced by IQGAP1.

Discussion
In this study, we found that the percentage of high expression of IQGAP1 in PDAC tissues was significantly higher than that in adjacent normal tissues, in line with previous results that IQGAP1 is elevated in PC17. Furthermore, high IQGAP1 expression was positively correlated with histological differentiation and N stage in PDAC. Some previous studies have reported that the overexpression of IQGAP1 is significantly associated with poor prognosis in advanced colorectal cancer20, ovarian carcinoma21 and glioma22. We revealed that PDAC patients with high IQGAP1 expression had shorter survival times than patients with low IQGAP1 expression and that high IQGAP1...
expression was an independent unfavorable prognostic biomarker of OS, suggesting the role of IQGAP1 a potential therapeutic target for PDAC.

IQGAP1 is a scaffold protein that interacts with distinct proteins to regulate cancer cell proliferation and migration\(^1\),\(^2\),\(^3\),\(^4\). IQGAP1 has also been reported to play important roles in regulating the microtubule network, actin cytoskeleton and cell adhesion\(^5\), IQGAP1 has been demonstrated to be regulated by miR-23b cluster, miR-125a-5p\(^2\), Long noncoding RNA (MIRAT)\(^2\), and promote RAS-MAP kinase-driven cancer invasion\(^2\). In addition, a significant increase in angiogenesis by the overexpression of IQGAP1 was found in an \textit{in vivo} mouse model of breast cancer\(^2\). Moreover, IQGAP1 SUMOylation can stabilize IQGAP1 by reducing protein ubiquitination and thus promote the development of colorectal cancer\(^2\). It has been reported that IQGAP1 interacts with K-Ras and increases ERK1/2 phosphorylation to modulate K-Ras pathway in PC\(^3\). Although Jin et al. have demonstrated that IQGAP1 expression is positively associated with the degree of metastasis of PC \textit{in vitro}\(^3\), to fully elucidate the possible functional significance of IQGAP1 in PC cell lines, we performed both gain- and loss-of-function assays. We observed that the knockdown of IQGAP1 in the two cell lines SW1990 and CFPAC-1 not only inhibited cell proliferation \textit{in vitro} but also suppressed tumor growth and metastasis \textit{in vivo}. Conversely, the upregulation of IQGAP1 enhanced proliferation and migration.

Depletion of IQGAP1 can decrease the Wnt-induced nuclear accumulation of \(\beta\)-catenin during early embryogenesis\(^1\), and IQGAP1 overexpression promotes the translocation of \(\beta\)-catenin into the nucleus in hepatocellular carcinoma\(^2\). In contrast, in human colon adenocarcinoma, IQGAP1 knockdown via siRNA cannot alter the expression levels and localization of \(\beta\)-catenin\(^2\). Our results showed that IQGAP1 knockdown can inhibit canonical Wnt signaling in PC cells as evidenced by decreased levels of both cytoplasmic and nuclear \(\beta\)-catenin, as well as the downstream target genes of \(\beta\)-catenin\(^3\). Our results indicated that the aberrant activation of the canonical Wnt signaling pathway is induced by IQGAP1 upregulation. These results indicate that IQGAP1 is critical for the progression of PC and plays an important role in the aberrant activation of the canonical Wnt/\(\beta\)-catenin pathway.

DVL is critical for protecting \(\beta\)-catenin from degradation in canonical Wnt signaling, where the interaction of DVL with both c-Jun and \(\beta\)-catenin promotes Wnt signaling-stimulated transcription\(^3\). DVL has three homologues (DVL1, 2 and 3). Some DVL2-associated oncoproteins, such as Forkhead box (FOX) transcription factors (FOXK1 and FOXK2)\(^2\), ataxia-telangiectasia group D complementing gene (ATDC)\(^3\), and RAP1B\(^3\), translocate DVL2 into the nucleus and therefore activate the Wnt/\(\beta\)-catenin signaling pathway. However, some negative regulators such as DVL-DEP domain-Interacting Protein (DDIP) destroy the TCF4/\(\beta\)-catenin complex\(^3\) and MLLT4 (AF6) independent of the canonical Wnt/\(\beta\)-catenin signaling pathway\(^3\) and ultimately inhibit cell proliferation. DVL2 has been demonstrated to contribute to PC tumorigenesis by inducing the stabilization of \(\beta\)-catenin\(^3\). Consistent with the result of other studies, our results revealed that DVL2 can interact with IQGAP1.
and that knockdown of DVL2 in PANC-1 cells overexpressing IQGAP1 can reverse the increase in β-catenin levels. By co-IP assays, we confirmed that IQGAP1 forms a complex with DVL2 and β-catenin and may mediate the interaction between DVL2 and β-catenin. We found that IQGAP1 can promote DVL2 nuclear translocation and regulate the protein level but not the mRNA level of DVL2, suggesting that changes in DVL2 stability play an important role in regulating the Wnt/β-catenin signaling pathway. However, the detailed mechanisms remain to be elucidated.

The loss of tumor cell-cell adhesion and gain of tumor invasion enabled by EMT initiates tumor metastasis. E-cadherin-mediated cell-cell adhesion has been proven to be reduced by the overexpression of IQGAP1 via direct interaction with CDC42 and Rac1. IQGAP1 has been documented to be tightly linked with the Wnt/β-catenin signaling pathway and to be involved in regulation of cell proliferation and EMT. DVL2 is responsible for the regulation of EMT in MCF-7 cells. However, the role of IQGAP1 and DVL2 in the regulation of EMT mediated by Wnt/β-catenin signaling remains obscure. In our study, we provided evidence that IQGAP1 augmented the expression of mesenchymal markers (N-cadherin and Vimentin) and EMT-activating transcription factors (Snail, Slug, Twist1 and ZEB1) while decreasing the expression of the epithelial marker E-cadherin. We also demonstrated that the knockdown of DVL2 inhibited EMT induced by IQGAP1 overexpression. Therefore, we concluded that IQGAP1 may serve an important mediator of EMT through DVL2.

In conclusion, this study indicated that the overexpression of IQGAP1 is associated with unfavorable clinicopathological features and poor survival in patients with PDAC. IQGAP1 can also promote pancreatic tumorigenesis and progression, making it an attractive therapeutic target or prognostic molecular biomarker of PDAC. Our findings show that IQGAP1 regulates Wnt/β-catenin signaling by interacting with DVL2 and β-catenin. Both in vitro and in vivo results extend our understanding of the underlying molecular mechanism of IQGAP1 in the regulation of EMT and cell proliferation mediated by Wnt/β-catenin signaling. To better reveal the intrinsic mechanism of IQGAP1-induced carcinogenesis, larger populations of patients, longer follow-up and further molecular studies in PC are still needed to support our findings.

Materials and Methods

Patients. Human PDAC samples and peritumor samples were obtained from the Department of Hepatobiliary Surgery, Lianyungang Clinical College of Nanjing Medical University. The patients were histopathologically diagnosed with primary PDAC and had not received any anticancer therapy before surgery. PDAC tumors were staged according to the 7th edition of International Union Against Cancer guidelines. Approval from ethics committee of Lianyungang Clinical College of Nanjing Medical University and informed consent from each patient were obtained before enrollment into the study. This study was performed in accordance with the Declaration of Helsinki.

Stable cell line construction. Based on the silencing effect of small interfering RNAs (siRNAs) against IQGAP1, we chose sense 5'-GGGACAAAGUGCCUGAACAU-3' and antisense 5'-AUGUUCAGGAUCUUUGCGC-3' to be inserted into the lentiviral expression vector hU6-MCS-Ubiquitin-EGFP-IRE-puromycin (Shanghai GenePharma, Co., Ltd., Shanghai, China). GFP in all lentiviral vectors was used to monitor transfection efficiency. SW1990 cells were seeded in 6-well plates and transfected with IQGAP1-targeting shRNA and negative control shRNA. Forty-eight hours after infection, the cells were treated with puromycin (1 μg/ml) for approximately two weeks to generate stable transfected cells.

Xenograft tumorigenicity assays. All male BALB/c nude mice, aged 4–6 weeks, used in this study were purchased from Model Animal Research Center at Nanjing University (Nanjing, China). All the animal protocols were reviewed and approved by the Animal Care Committee of Nanjing University in accordance with the guidelines of the Institutional Animal Care and Use Committee. To assess tumor growth, we subcutaneously implanted SW1990 cells (5 × 10⁶) into the mice (6 mice per group). The mice were randomly divided into two groups after 4 days of tumor implantation. Tumor volume was calculated by the following formula: volume = (length × width²)/2. For metastasis study, SW1990 cells (1 × 10⁶) in 50 μL phosphate-buffered saline were orthotopically injected into the major pancreatic duct (8 mice per group). Three months after injection, the mice were euthanized, and suspected metastatic tissues were subjected to hematoxylin and eosin (H&E) staining for the pathologic examination of metastatic nodules.

Others. For reagents, cell lines and cell culture, tissue microarray (TMA) construction, immunohistochemistry and scoring, small interfering RNA and plasmid vector-related assays, quantitative real-time reverse transcription polymerase chain reaction, western blotting, CCK-8 assay, colony formation assay, wound healing assay, transwell migration assay, co-immunoprecipitation (co-IP) experiments, and immunofluorescence imaging, please see Supplemental File.

Statistical analysis. Associations of categorical data between IQGAP1 expression and clinicopathological features were assessed using the chi-square test and Fisher’s exact test. Possible differences in overall survival (OS) were examined by the Kaplan-Meier analysis and log-rank test. Prognostic factors associated with OS in univariate analysis were evaluated using Cox regression models for multivariate analysis. Student’s t-tests were used to determine the differences between two independent groups, and the results were expressed as the mean ± SD. All statistical analyses were performed using SPSS 23 statistical software (SPSS Inc, Chicago, IL, USA). P value < 0.05 was considered statistically significant.

Data Availability All data generated or analyzed during this study are available from the corresponding author on reasonable request.
References

1. Hidalgo, M. Pancreatic cancer. N Engl J Med 362, 1605–1617 (2010).
2. Siegel, R. L., Miller, K. D. & Jemal, A. Cancer statistics, 2016. CA Cancer J Clin 66, 7–30 (2016).
3. Hackert, T., Ulrich, A. & Buchler, M. W. Borderline resectable pancreatic cancer. CANCER LETT 375, 231–237 (2016).
4. Chen, R. et al. Disrupting glutamine metabolic pathways to sensitize gemcitabine-resistant pancreatic cancer. Sci Rep 7, 7950 (2017).
5. Yang, Y. et al. Endoscopic ultrasound-guided fine needle core biopsy for the diagnosis of pancreatic malignant lesions: a systematic review and Meta-Analysis. Sci Rep 6, 22978 (2016).

11. Dong, P. et al. Overexpression and diffuse expression pattern of IQGAP1 at invasion fronts are independent prognostic parameters in ovarian carcinomas. Cancer Lett 233, 120–127 (2006).

12. McDonald, K. L. et al. IQGAP1 and IGBP2: valuable biomarkers for determining prognosis in glioma patients. J Neuropathol Exp Neurol 66, 405–417 (2007).

13. Chen, F. et al. IQGAP1 is overexpressed in hepatocellular carcinoma and promotes cell proliferation by Akt activation. Exp Mol Med 42, 477–483 (2010).

14. Yamaoka-Tojo, M. et al. IQGAP1, a novel vascular endothelial growth factor receptor binding protein, is involved in reactive oxygen species–dependent endothelial migration and proliferation. CIRC RES 95, 276–283 (2004).

15. Naidu, S. et al. PDGFR-modulated miR-23b cluster and miR-125a-5p suppress lung tumorigenesis by targeting multiple components of KRAS and NF-κB pathways. Sci Rep 7, 15441 (2017).

16. Sanlorenzo, M. et al. The lncRNA MIRAT binds to IQGAP1 and modulates the MAPK pathway in NRAS mutant melanoma. Sci Rep 8, 10902 (2018).

17. Jameson, K. L. et al. IQGAP1 scaffold–kinase interaction blockade selectively targets RAS-MAP kinase–driven tumors. Nat Med 19, 626–630 (2013).

18. Jadeski, L., Mataraza, J. M., Jeong, H. W., Li, Z. & Sacks, D. B. IQGAP1 stimulates proliferation and enhances tumorigenesis of human breast epithelial cells. J Biol Chem 283, 1008–1017 (2008).

19. Liang, Z. et al. Sumoylation of iqgap1 promotes the development of colorectal cancer. Cancer Lett 411, 90–99 (2017).

20. Matsunaga, H., Kubota, K., Inoue, T., Isono, F. & Ando, O. IQGAP1 selectively interacts with K-Ras but not with H-Ras and modulates K-Ras function. Biochem Biophys Res Commun 444, 360–364 (2014).

21. Jin, L., Liu, X., Zhou, J. & Chen, J. Potential involvement of IQGAP1 in proliferation and metastasis of human pancreatic cancer. Front Biosci (Landmark Ed) 21, 1076–1083 (2016)

22. Jin, X. et al. The Overexpression of IQGAP1 and beta-Catenin Is Associated with Tumor Progression in Hepatocellular Carcinoma In Vitro and In Vivo. Plos One 9, e96501 (2014).

23. Gu, X. et al. Nuclear Dvl, c-Jun, beta-catenin, and TCF form a complex leading to stabilization of beta-catenin–TCF interaction. J Cell Biol 180, 1087–1100 (2008).

24. Wang, W. et al. FOXKs promote Wnt/beta-catenin signaling by translocating DVL into the nucleus. Dev Cell 32, 707–718 (2015).

25. Wang, L. et al. Oncogenic function of ATDC in pancreatic cancer through Wnt pathway activation and beta-catenin stabilization. Cancer Cell 15, 207–217 (2009).

26. Jia, Z. et al. RAP1B, a DVL2 binding protein, activates Wnt/beta-catenin signaling in esophageal squamous cell carcinoma. Gene 611, 15–20 (2017).

27. Zhang, H. et al. Dishedvelled–DEP domain interacting protein (DDIP) inhibits Wnt signaling by promoting TCF4 degradation and disrupting the TCF4/beta-catenin complex. Cell Signal 22, 1753–1760 (2010).

28. Xu, Y. et al. Loss of polarity protein AF6 promotes pancreatic cancer metastasis by inducing Snail expression. Nat Commun 6, 7184 (2015).

29. Kuroda, S. et al. Role of IQGAP1, a target of the small GTPases Cdc42 and Rac1, in regulation of E-cadherin–mediated cell-cell adhesion. SCIENCE 281, 832–835 (1998).

30. Su, D., Liu, Y. & Song, T. Knockdown of IQGAP1 inhibits proliferation and epithelial-mesenchymal transition by Wnt/beta-catenin pathway in thyroid cancer. Onco Targets Ther 10, 1549–1559 (2017).

31. Geng, Y. et al. Insulin receptor substrate 1/2 (IRS1/2) regulates Wnt/beta-catenin signaling through blocking autophagic degradation of dishedvelled2. J Biol Chem 289, 11230–11241 (2014).

Acknowledgements

We thank Translational Medicine Core facilities of Medical School of Nanjing University for instruments supporting. The research was supported by the National Natural Science Foundation of China (81573293, 81602093, 81602054), the Key Project supported by Medical Science and Technology Development Foundation, Nanjing Municipality Health Bureau (ZKXX15020, ZKXX17022), the National Science Foundation of Jiangsu Province (BK20151042 and BK20160118), the National Basic Research Program of China (973 Program,
2013CB834100), the Primary Research & Development Plan of Jiangsu Province (BE2018701), the Young Talents Hausen Fund of Lianyungang Clinical College of Nanjing Medical University (QN150102), the Foundation of Health and Family planning Commission of Lianyungang (201802), and the Fundamental Research Funds for the Central Universities (021414380215, 021414380329 and 020414380080).

**Author Contributions**
Conception and design: W.H., J.H.W., C.P.J.; Development of methodology: W.H., Z.X.W., S.Z.; Acquisition and analysis of data and drafting of the manuscript: W.H., J.Y.W., S.Z., X.L., K.Y.Y., A.L.J., W.L.; Analysis and interpretation of experimental data: W.H., Z.X.W., J.H.W.; Writing, review, and/or revision of the manuscript: W.H., Z.X.W., J.H.W.; Study supervision: Z.W., J.H.W., C.P.J.

**Additional Information**
Supplementary information accompanies this paper at [https://doi.org/10.1038/s41598-019-44048-y](https://doi.org/10.1038/s41598-019-44048-y).

**Competing Interests:** The authors declare no competing interests.

**Publisher’s note:** Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

[Open Access] This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit [http://creativecommons.org/licenses/by/4.0/](http://creativecommons.org/licenses/by/4.0/).

© The Author(s) 2019